Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.52 |
| ▸ | PTGIR | P43119 | 2/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.52 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137504 | 0.90 | PTGDR2 (0.69) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| SCHEMBL1946099 | 0.86 | PTGDR2 (0.53) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| SCHEMBL1011312 | 0.86 | PKM (0.40) | PTGDR2CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL1942958 | 0.82 | PTGDR2 (0.56) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| SCHEMBL1011325 | 0.82 | PTGDR2 (0.49) | PTGDR2CYP3A4PTGDRKMT2A | |
| SCHEMBL2278005 | 0.82 | CYP1A2 (0.43) | CYP3A4CYP1A2CYP2C19KMT2A | |
| SCHEMBL1944250 | 0.81 | KMT2A (0.43) | CYP3A4CYP2C9CYP1A2CYP2C19BCHE | |
| SCHEMBL349573 | 0.81 | CYP3A4 (0.45) | CYP3A4CYP1A2CYP2C19BCHEACHE | |
| SCHEMBL137331 | 0.80 | PTGDR2 (0.71) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| SCHEMBL140410 | 0.80 | PTGDR2 (0.85) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426449-B2 | Aminoalkylphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426449-B2 | Aminoalkylphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426449-B2 | Aminoalkylphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CYP3A4 1269/4885CYP2C9 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.